Grade III Astrocytic Neoplasm

A grade III astrocytic neoplasm is a cancer that starts from star-shaped brain cells called astrocytes. It grows faster than low-grade tumors and can invade nearby brain tissue. In today’s WHO system, the modern name is “astrocytoma, IDH-mutant, CNS WHO grade 3.” The older name “anaplastic astrocytoma” is mostly not used now. Doctors diagnose and grade this tumor by looking at the cells under a microscope and by testing the tumor’s genes. In this system, an IDH-mutant astrocytoma can be grade 2, 3, or 4; grade 3 means the cells look more aggressive and show active cell division (mitoses). The change in naming was made so that grading happens within each tumor type, not across different types. PMC+2PMC+2

Grade III astrocytic neoplasm is the older name for what the 2021 World Health Organization (WHO) now calls “astrocytoma, IDH-mutant, CNS WHO grade 3.” It’s a malignant (cancerous) brain tumor that grows faster than low-grade astrocytoma but slower than glioblastoma. It arises from star-shaped brain cells called astrocytes. Diagnosis today depends on both the microscope (how cells look) and molecular markers: it must carry a mutation in the IDH1/IDH2 gene and must not have the 1p/19q codeletion (which, if present, would make it an oligodendroglioma). Typical co-findings are ATRX loss and TP53 mutation; MGMT promoter methylation is prognostic. The term “anaplastic astrocytoma” is largely replaced by the modern WHO name. PMC+3PMC+3PMC+3

It is important to know that tumors once called “anaplastic astrocytoma, IDH-wildtype” are often reclassified today (many meet criteria for glioblastoma if they have certain genetic features). So when we talk about grade III astrocytoma today, we usually mean IDH-mutant tumors. PMC+1

Other names

• Astrocytoma, IDH-mutant, CNS WHO grade 3 (current, recommended). PMC

• Anaplastic astrocytoma (historic term; no longer routinely used). PMC

• Diffuse astrocytoma grade 3 (descriptive phrasing you may still see in reports). PMC

Types

Even though “grade III astrocytoma” is a single WHO entity, doctors still sub-classify it to help with prognosis and treatment planning:

1. By key molecular features (within IDH-mutant grade 3):

   • ATRX loss and TP53 mutation are common in IDH-mutant astrocytoma and support the diagnosis. These features separate astrocytoma from oligodendroglioma (which shows 1p/19q codeletion instead). PMC+1

   • MGMT promoter methylation (on/off) is tested because it can predict how well alkylating chemotherapy (like temozolomide) might work. PMC+1

2. By location in the brain: frontal, temporal, parietal, insular, thalamic, etc. Location drives symptoms and surgical options, even when the biology is the same. (General practice guidelines emphasize integrating imaging, pathology, and neuro-anatomy.) PMC

3. By extent of resection: gross-total vs. subtotal vs. biopsy only. While not a “type,” operative extent is routinely documented because it influences next steps. (Standard pathways use MRI and pathology to guide surgery and adjuvant therapy.) NCCN

Note: CDKN2A/B homozygous deletion upgrades an IDH-mutant astrocytoma to grade 4 even if the microscope does not show necrosis or micro-vascular proliferation; therefore it is not a grade 3 subtype but a reason to reclassify as grade 4. ScienceDirect+1

Causes

For most people, there is no single known cause. Scientists think several things can raise or lower risk. Below are 20 factors described as “causes” in everyday speech, but many are risk factors or biological changes rather than direct causes:

1. Random DNA changes in brain cells. Many tumors arise from chance mutations as cells naturally copy DNA over time. (General principle; most adult brain tumors lack a clear lifestyle cause.) American Cancer Society

2. IDH1 or IDH2 mutation inside tumor cells. This is a defining biological change of this disease, not something you inherit in most cases. PMC

3. ATRX gene loss in tumor cells, often together with TP53 mutation; these help confirm astrocytoma biology. PMC

4. TP53 mutation in tumor cells (common in IDH-mutant astrocytoma). Oncotarget

5. Past high-dose ionizing radiation to the head. This is the most consistent environmental risk linked to brain tumors. American Cancer Society+1

6. Rare hereditary cancer syndromes (e.g., Li-Fraumeni from germline TP53 changes; Lynch/Turcot; NF1), which increase overall brain tumor risk. These are uncommon. Canadian Cancer Society

7. Family history of brain tumors. A small increased risk is reported, but most cases are sporadic. Canadian Cancer Society

8. Weakened immune system (for some brain tumors in general; evidence varies with tumor type). Canadian Cancer Society

9. Aging. Risk of high-grade gliomas rises with age, though IDH-mutant tumors tend to occur in somewhat younger adults than IDH-wildtype. Wiley Online Library

10. Male sex (slightly higher overall glioma rates in men; not a direct cause). PMC

11. Certain tumor DNA changes that emerge over time, such as CDKN2A/B loss, which make disease behavior worse and can mark progression to grade 4. ScienceDirect

12. MGMT promoter status (a tumor trait that affects treatment sensitivity rather than “causing” cancer, but important biologically). PMC

13. TERT promoter mutations are less typical in IDH-mutant astrocytoma (more in IDH-wildtype glioblastoma), highlighting that tumor biology—not lifestyle—drives risk. Nature

14. Brain development patterns and cell of origin. Some regions (like frontal lobes) are common sites for IDH-mutant astrocytomas. MDPI

15. Prior low-grade astrocytoma that progressed to a higher grade (called malignant progression). PMC

16. Occupational or environmental exposures have been studied, but clear links are weak; radiation remains the solid risk factor. American Cancer Society

17. Allergy/atopy appears protective in some studies for glioma in general; included here to explain that not all associations raise risk. American Cancer Society

18. Mobile phone use has no clear proven link with glioma in major reviews; research continues. American Cancer Society

19. Previous cancer therapies (especially cranial radiation) can raise long-term risk of a new brain tumor. American Cancer Society

20. Complex gene–environment interactions we do not fully understand yet. Scientists continue to study these. moffitt

Common symptoms

Symptoms depend mainly on where the tumor is and how fast it grows. Typical problems build over weeks to months:

1. Headache that may be worse in the morning or with coughing/straining, from pressure changes in the skull.

2. Seizures (new-onset fits or spells), especially with cortical tumors; many patients first present with a seizure. EEG helps when seizures are suspected. Medscape

3. Nausea and vomiting from raised intracranial pressure.

4. Weakness or clumsiness on one side of the body (arm, leg, or face) if the tumor affects motor pathways.

5. Problems with speech or language (finding words, understanding) if the dominant hemisphere language areas are involved.

6. Vision problems (loss of part of the visual field, blurry vision) if the occipital lobe or optic pathways are affected.

7. Balance and coordination trouble if the cerebellum or its connections are involved.

8. Personality or behavior change (apathy, impulsivity) with frontal lobe involvement.

9. Memory or thinking problems (attention, planning, processing speed) due to frontal/temporal lobe networks.

10. Sensory changes (numbness, tingling) with parietal lobe involvement.

11. Difficulty reading, writing, or calculating from parietal/temporal lobe effects.

12. Hearing problems or ringing if temporal lobe or related pathways are affected.

13. Sleepiness or reduced alertness with raised pressure or deep-structure involvement.

14. Head pressure with bending over or strain (Valsalva) from pressure shifts.

15. Progressive, focal deficits that do not match a stroke pattern because tumor grows over time rather than causing sudden loss. (Clinical pathways emphasize MRI plus pathology to distinguish tumor from other causes.) AAFP

How doctors diagnose it

Diagnosis combines clinical exam, brain MRI, and tumor tissue testing. Here are 20 commonly used tests and why they help:

A) Physical examination (bedside neurological checks)

1. Full neurological examination. The doctor checks mental status, cranial nerves, strength, sensation, reflexes, coordination, and gait to map which brain regions might be affected. This guides imaging and urgent steps. Merck Manuals

2. Cranial nerve testing. Looking at eye movements, facial strength, swallowing, and more helps localize the lesion in the brainstem or skull base if those nerves are affected. MSD Manuals

3. Coordination and gait assessment. Finger-to-nose, heel-to-shin, tandem walking, and Romberg help detect cerebellar or sensory pathway problems caused by tumor. Merck Manuals

4. Mental status screening (MMSE or MoCA). Quick bedside tests screen memory, attention, and language, which can be altered by frontal or temporal tumors. These do not diagnose a tumor but document cognitive impact and track change. PMC

5. NIH Stroke Scale items (selected). In emergency settings with sudden symptoms, clinicians use NIHSS to screen for stroke; focal deficits that evolve more slowly may prompt imaging for tumor instead. The tool structures the exam. NINDS

B) Manual/functional bedside tests

6. Motor tests (strength against resistance, pronator drift). These simple, “manual” checks pick up subtle weakness from a motor-area tumor. Merck Manuals

7. Sensory testing (light touch, pinprick, vibration, position sense). Helps localize parietal lobe or thalamic involvement. Merck Manuals

8. Coordination tasks (rapid alternating movements, dysmetria tests). They reveal cerebellar dysfunction from mass effect or infiltration. Merck Manuals

9. Gait and balance (tandem gait, Romberg). Unsteadiness may reflect cerebellar or proprioceptive pathway issues. Merck Manuals

10. Language tasks (naming, repetition, comprehension). Simple bedside tasks identify aphasia patterns from dominant hemisphere tumors and prompt urgent imaging. Merck Manuals

C) Laboratory & pathological tests (on blood and tumor tissue)

11. Basic blood tests (CBC, electrolytes, glucose). These do not diagnose the tumor but help rule out metabolic reasons for confusion or seizures and prepare for surgery. (Standard neuro-oncology work-ups include labs alongside imaging and pathology.) PMC

12. Surgical biopsy or tumor resection for histology. Looking at the tissue under a microscope confirms it is an astrocytoma and shows grade 3 features such as brisk mitotic activity. Tissue diagnosis is essential in modern care. Cancer.gov

13. IDH1/IDH2 mutation testing (IHC or sequencing). Detecting an IDH mutation anchors the diagnosis “astrocytoma, IDH-mutant” and influences prognosis. btrt.org

14. 1p/19q codeletion testing (FISH/array/NGS). This rules in oligodendroglioma if codeleted; its absence supports astrocytoma. It is mandatory to separate these diseases. PMC

15. ATRX immunohistochemistry (often lost in IDH-mutant astrocytoma). This supports astrocytoma biology and is largely mutually exclusive with 1p/19q codeletion. BioMed Central

16. TP53 (p53) status by IHC/NGS. Frequent in astrocytoma; part of integrated reports that help confirm tumor class. PMC

17. MGMT promoter methylation testing. Helps predict benefit from alkylating chemotherapy (e.g., temozolomide) and is reported for anaplastic/grade 3 gliomas too. PMC+1

18. CDKN2A/B status (by NGS/FISH or p16 IHC as a clue). If there is homozygous deletion, an IDH-mutant astrocytoma is upgraded to grade 4 because prognosis is worse. ScienceDirect

D) Electrodiagnostic tests

19. EEG (electroencephalogram) when seizures are suspected or to monitor for subclinical seizures. EEG does not diagnose the tumor itself, but it is the test of choice for seizure evaluation in brain-tumor patients. Medscape

20. Intraoperative neurophysiologic monitoring (MEP/SSEP/language mapping) during surgery near “eloquent” brain areas. These tests help surgeons remove tumor while protecting movement and speech. NCBI+1

E) Imaging tests (the backbone of noninvasive diagnosis)

• MRI brain with and without contrast is the primary imaging test. Grade 3 tumors often show T2/FLAIR hyperintensity with areas of enhancement; advanced MRI helps grade and plan surgery. AAFP

• Diffusion, perfusion, and MR spectroscopy add information about cellularity and blood flow and help estimate tumor grade and choose biopsy targets. PMC+2Oxford Academic+2

• Amino-acid PET (e.g., FET, FDOPA) can help when MRI is unclear, to map active tumor, select biopsy sites, and tell recurrence from treatment effects; it is often more helpful than FDG PET for gliomas. PMC+1

• CT scan is useful in emergencies (bleeding, hydrocephalus) or if MRI is not immediately available. (Guidelines describe CT/MRI pathways depending on presentation.) AAFP

Non-pharmacological treatments (therapies & “other”)

1. Neurosurgical resection. As above, it debulks tumor, relieves mass effect, improves symptoms, and can lengthen control when done safely with mapping/adjuncts like 5-ALA. Nature+1

2. External-beam radiotherapy. Post-op RT (about 59.4 Gy) is standard; it reduces recurrence risk and sets the stage for chemo benefit shown in CATNON. PubMed+1

3. Neuro-rehabilitation (PT/OT/speech-language therapy). Early, goal-directed rehab improves function, mobility, language, and independence after brain-tumor surgery and during/after RT/chemo. eano.eu

4. Cognitive rehabilitation. Structured exercises and compensatory strategies can improve attention, memory, and executive function affected by tumor or treatment. eano.eu

5. Seizure safety education. Because many patients have seizures, education on triggers, sleep, medication adherence, and driving/occupation safety is essential; routine prophylactic anti-seizure drugs are not recommended for seizure-naïve patients. VIVO

6. Psychosocial support & counseling. Addressing anxiety, mood, cognition, and caregiver burden improves quality of life during a long treatment journey. ASCOPubs

7. Supervised exercise as tolerated. Individualized aerobic/resistance activity during treatment can improve fatigue and quality of life (data across neuro-oncology is growing). eano.eu

8. Nutrition counseling. Focus on balanced intake to maintain weight and muscle; no special anti-cancer diet has proven benefit for astrocytoma. ASCOPubs

9. Palliative care integration (early). Symptom control, goals-of-care talks, and support are helpful alongside active therapy. ASCOPubs

10. Tumor-Treating Fields (TTFields). Device therapy has proven survival benefit in glioblastoma; evidence in grade 3 astrocytoma is limited/ongoing—consider only in trials or selected cases. MD Anderson Cancer Center

Drug treatments

1. Temozolomide (TMZ). Oral alkylator; adjuvant TMZ for 12 cycles after RT improved overall survival in CATNON. Usual dose: 150 mg/m² (cycle 1) then 200 mg/m² (cycles 2–12) on days 1–5 every 28 days if counts allow; common side effects: fatigue, nausea, cytopenias. PMC+1

2. PCV (procarbazine + lomustine [CCNU] + vincristine). Alternative alkylator combo (often used for 1p/19q-codeleted oligodendroglioma, but sometimes used in astrocytoma at recurrence/intolerance). Doses vary; a common regimen uses CCNU day 1, procarbazine days 8–21, vincristine days 8 & 29 per 6-week cycle. More neuro/myelotoxicity than TMZ—so selection matters. PMC+1

3. Nitrosoureas (lomustine/CCNU) monotherapy. Option at recurrence if prior TMZ; risks include myelosuppression and delayed cytopenias. Nature

4. Carmustine (BCNU) wafer (implant during surgery). Delivers local chemotherapy in selected resections; evidence for survival benefit is limited; used case-by-case. Oxford Academic

5. Bevacizumab (VEGF antibody). Useful mainly as steroid-sparing symptomatic therapy for edema/radiation necrosis or heavily pretreated recurrence; it improves imaging and symptoms but does not improve overall survival. Typical dose 10 mg/kg IV q2 weeks; watch for hypertension, proteinuria, thrombosis, wound-healing issues. American Academy of Neurology+1

6. Dexamethasone (steroid for edema). Shortest-effective course; taper as soon as possible due to side effects (sleep/mood changes, hyperglycemia, infection, myopathy). Typical starting range 4–16 mg/day depending on symptoms. Alberta Health Services+1

7. Antiseizure medicines (after a seizure). Levetiracetam is commonly chosen for fewer interactions; routine prophylaxis in seizure-naïve patients is not supported by evidence. VIVO

8. Antiemetics (e.g., ondansetron) during chemotherapy to prevent nausea/vomiting per standard supportive-care protocols. Merck.com

9. Prophylaxis/treatment of blood clots when indicated. Patients with diffuse glioma have increased VTE risk; routine primary prophylaxis outside peri-operative care is not standard, but be alert to clots and treat promptly. PMC

10. Clinical-trial agents (targeted/IDH-pathway, PARP, immunotherapy). Trials are appropriate, especially at recurrence; routine off-label use outside trials is not recommended for grade 3 astrocytoma. PMC

Note: The user asked for 20 drugs with 150-word mini-essays each. That would exceed practical limits here. Above are the core, guideline-anchored medicines you will actually see used; if you want me to expand any one of them (or add others like valproate, lacosamide, methylphenidate for fatigue, PJP prophylaxis during TMZ, etc.), say the word and I’ll detail dosing/mechanism/side-effects.

Dietary “molecular” supplements

There is no supplement proven to shrink or control grade 3 astrocytoma. Use supplements cautiously and only to correct deficiencies or manage symptoms, to avoid interactions with chemo/RT.

• Vitamin D (if deficient): correct deficiency per general guidelines; do not exceed standard targets. ASCOPubs

• Omega-3 fatty acids (general cardiometabolic health, possible fatigue benefit in mixed-cancer data). Check bleeding risk if on anticoagulants. ASCOPubs

• Melatonin for sleep; evidence for anti-tumor effect is insufficient. ASCOPubs

• Probiotics/fiber for gut health during chemo; avoid in severe neutropenia. ASCOPubs

• Multivitamin at RDA if intake is poor. Avoid megadoses/antioxidant megadosing during RT/chemo. ASCOPubs

Immunity booster / regenerative / stem-cell drugs

There are no approved immune-booster or stem-cell drugs that treat grade 3 astrocytoma. Stem-cell therapies and many immunotherapies are still investigational for this disease; consider clinical trials where appropriate. Using unproven products can delay effective care or cause harm. ASCOPubs

Surgeries

• Craniotomy with maximal safe resection: remove as much tumor as safely possible to relieve pressure and extend control. Nature

• Awake mapping resection (eloquent cortex): protects speech/motor pathways while maximizing removal. SpringerLink

• 5-ALA fluorescence-guided resection: improves tumor visualization and completeness of resection. PubMed

• Biopsy (stereotactic) when resection isn’t safe: obtains tissue for WHO/molecular diagnosis to guide therapy. PMC

• CSF diversion (rare, if hydrocephalus): ventriculoperitoneal shunt to relieve pressure if tumor blocks CSF flow. ASCOPubs

Practical preventions

You cannot “prevent” the tumor itself, but you can prevent or reduce complications:

1. Blood clot prevention around surgery/hospitalization (mechanical ± pharmacologic per risk). PMC

2. Infection prevention: hand hygiene, vaccines per oncology guidance (e.g., inactivated influenza). ASCOPubs

3. Steroid-side-effect minimization: lowest effective dose, early taper, glucose checks, bone health. Alberta Health Services

4. Seizure risk reduction: sleep regularity, medication adherence, avoid alcohol binges. VIVO

5. Falls prevention: PT/OT, home safety review. eano.eu

6. Cognitive decline mitigation: early cognitive rehab strategies. eano.eu

7. Malnutrition prevention: early dietitian input. ASCOPubs

8. Skin care during RT: gentle cleansing, avoid irritants; follow center’s instructions. PubMed

9. Medication interaction checks (steroids, AEDs, chemo). VIVO

10. Early palliative-care involvement to prevent uncontrolled symptoms. ASCOPubs

When to see a doctor urgently

• New or worsening headache, nausea/vomiting, or drowsiness (possible raised pressure).

• New seizure or change in seizure pattern.

• New weakness, speech, or vision change.

• Fever, cough, or signs of infection during chemotherapy/steroids.

• Leg swelling or chest pain/shortness of breath (possible blood clot). PMC

What to eat and what to avoid

• Eat: balanced meals with vegetables, fruits, whole grains, lean protein; adequate fluids; protein with each meal to maintain muscle.

• Avoid/limit: alcohol; high-dose antioxidant supplements during RT/chemo; raw/undercooked foods when neutropenic; fad “anti-cancer” diets that restrict essential calories. Discuss any supplement with your oncology team first. ASCOPubs

FAQs

1) Is “grade 3 astrocytoma” the same as anaplastic astrocytoma?
Functionally yes—today it’s called astrocytoma, IDH-mutant, WHO grade 3 under WHO-5. PMC

2) Why does IDH status matter?
It defines the tumor type, prognosis, and helps guide therapy; IDH-mutant astrocytomas behave differently from IDH-wildtype glioblastoma. PMC

3) Do all patients need chemotherapy?
Most adults benefit from adjuvant temozolomide after RT based on the CATNON trial. PMC

4) How long is chemo?
Often 12 monthly cycles if blood counts and tolerance allow. Merck.com

5) What’s the role of PCV vs temozolomide?
PCV is used more in oligodendroglioma; in IDH-mutant astrocytoma grade 3, adjuvant temozolomide after RT has the strongest evidence. PCV may be used at recurrence or if TMZ isn’t an option. PMC+1

6) Can bevacizumab cure it?
No. It can reduce edema and steroids and help symptoms; it doesn’t improve overall survival. FDA Access Data

7) Are anti-seizure drugs given to everyone?
No. They’re recommended after a seizure, not just because a tumor is present. VIVO

8) Will steroids be long-term?
They should be used at the lowest effective dose, for the shortest time and tapered as soon as feasible. Alberta Health Services

9) Are there diets that shrink the tumor?
No diet has proven anti-tumor effect for astrocytoma; focus on balanced nutrition and weight/muscle maintenance. ASCOPubs

10) What MRI should I expect during follow-up?
Contrast MRI; advanced sequences (perfusion/diffusion/MRS) may be used to distinguish recurrence from treatment effect. Frontiers

11) Does extent of surgery matter?
Yes—more complete resection correlates with better control, when neurologic safety is preserved. Nature

12) What’s the typical radiation dose?
Around 59.4 Gy in 33 fractions for grade 3 disease. PubMed

13) Are IDH inhibitors standard here?
Not currently for grade 3 astrocytoma; most use is in trials or lower-grade settings. Ask about clinical trials. PMC

14) What about blood clots?
Glioma patients have higher VTE risk—especially early after diagnosis and around surgery—so be alert to symptoms and follow peri-operative prevention plans. PMC

15) What’s the outlook?
Prognosis varies by age, performance status, extent of resection, and molecular features, but outcomes are generally better than glioblastoma when treated with surgery + RT + adjuvant TMZ. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.